Compare PARK & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PARK | ONCY |
|---|---|---|
| Founded | 1972 | 1998 |
| Country | United States | Canada |
| Employees | 1212 | N/A |
| Industry | Misc Health and Biotechnology Services | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.5M | 107.3M |
| IPO Year | N/A | 2002 |
| Metric | PARK | ONCY |
|---|---|---|
| Price | $18.50 | $0.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 22.5K | ★ 1.5M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.06 | N/A |
| Revenue Next Year | $6.17 | $2,505.00 |
| P/E Ratio | $6.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.29 | $0.77 |
| 52 Week High | $22.68 | $1.51 |
| Indicator | PARK | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 39.59 |
| Support Level | $18.81 | N/A |
| Resistance Level | $21.06 | $1.06 |
| Average True Range (ATR) | 1.29 | 0.07 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 17.29 | 4.27 |
Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.